MiniMed Vivera (next-generation SmartGuard algorithm)
MiniMed
The right ambition. Almost none of the evidence yet.
MiniMed's next-generation control algorithm — the company's first serious move toward a fully closed loop. Vivera is designed to make the meal bolus *optional*: it can detect and dose for a meal on its own, take a simple meal announcement, or accept a traditional carb count. It was unveiled in March 2026 on a small feasibility study (14 adults and 13 children over three months) and no time-in-range results have been published. Its two head-to-head pivotal trials had not started as of July 2026. A software update delivering Vivera to existing MiniMed 780G and MiniMed Flex users is reported for 2027 — by a conference recap, not by MiniMed. It is not cleared anywhere.
The scorecard
No time-in-range results have been published for Vivera in type 1 diabetes at all. The feasibility study was 27 people over three months, and the registered trials are powered for *non-inferiority* in time in range (70–180 mg/dL / 3.9–10.0 mmol/L) against the system the person is already using — so the honest expectation is parity with less burden, not a higher ceiling.[2]
Vivera inherits SmartGuard's predictive low management, which has a good track record on the 780G, but no Vivera-specific time-below-range or severe-hypoglycemia data has been published. An algorithm that doses for meals it detects itself has to be judged on its own lows, not its predecessor's.[1]
The defining claim, and a real one: meal bolusing becomes optional, with automatic detection and dosing of unannounced meals. No other major manufacturer has committed to shipping that to an installed base. Scored below the fully-closed-loop research frontier because Vivera's version has only been shown in a 27-person feasibility study with no published outcomes.[1]
Vivera is software, so its wearability is whatever it runs on: the tubed 780G and the tubed, screenless, phone-controlled MiniMed Flex. Freer than a classic pump body thanks to app control, but still tubed — the tubeless MiniMed Fit is a separate, later programme.[5]
No mean glucose, GMI or HbA1c results have been published. The only public efficacy datum is a single anecdote — one 13-year-old reported going from 8% to 6.7% HbA1c — which is not evidence of anything at population level.[1]
Machine-learning adaptation plus automatic meal dosing is exactly the recipe for flatter post-meal curves, and that is the point of the design — but it is untested at scale and nothing has been published.[1]
No Vivera-specific exercise data. Unannounced activity is the hardest remaining problem for any algorithm that is also dosing for meals it detected itself, so this is scored cautiously until results exist.
Three meal-handling modes — no bolus, a simple announcement, or a full carb count — is genuine user choice, and more than most systems offer. But it remains a closed MiniMed ecosystem with no access to the algorithm's internals.[1]
Not cleared by any regulator, not available anywhere, and not yet reachable through a started trial under its own name. The 2027 software update to the 780G and Flex is a reported expectation from a conference recap, not a MiniMed commitment — the company has published no submission date.[5]
Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.
Editor’s take
Vivera is the most important thing a large pump manufacturer has said out loud in years: the meal bolus should be optional. That is the burden people with type 1 diabetes actually carry every day, and MiniMed is the first of the big companies to promise to lift it for an installed base rather than for a research cohort. We want this to work. But look at what exists in July 2026 — an ATTD presentation, 27 people, three months, zero published time-in-range numbers, and two head-to-head trials that had not started. And read the endpoints: both registered trials are powered for *non-inferiority*, meaning the bar MiniMed has set itself is "no worse than what you already have, with less work". That is an honest and worthwhile bar — the prize here is burden, not a higher ceiling — but it is not the same thing as a fully closed loop that beats a hybrid one. Judge this record again when the first per-arm outcomes land.
The full picture
Every automated insulin delivery system on sale today is a hybrid closed loop: the algorithm runs your background insulin and fires corrections, but you still have to announce every meal. Vivera is MiniMed's answer to that — a third-generation control algorithm, using machine learning to adapt to the individual, in which the meal bolus becomes optional. You can let it detect the meal and dose for it, give it a simple "I'm eating" announcement, or carry on counting carbs exactly as you do now.1
It is software, not hardware. It is designed to run on pumps MiniMed already sells — the 780G and the newer screenless, phone-controlled MiniMed Flex — which is what makes it different from every other fully-closed-loop effort. Most of those are research systems reaching dozens of people. This one is aimed at an installed base of hundreds of thousands.
What has actually been shown
Very little, and it is important to be blunt about that.
Vivera was unveiled on 12 March 2026 at the ATTD conference in Barcelona. The evidence behind the unveiling was a feasibility study of 14 adults and 13 children over three months. No time-in-range results have been published from it. No mean glucose, no HbA1c, no time-below-range. The single public efficacy datum in the coverage is an anecdote — one 13-year-old reported going from an HbA1c of 8% to 6.7%.1
You may see figures circulating in secondary coverage claiming roughly 74% time in range without meal announcement and 82% with. We have not been able to trace those to any primary source, so we do not publish them and neither should anyone else.
The trials — and what they are really testing
The registries are the clearest window on where this programme stands, with one important caveat: no registry record uses the name "Vivera". They all call the system the MiniMed NMX8 or the "Novel Medtronic Experimental AID System". The Vivera↔NMX8 link comes from press and manufacturer communication, not from ClinicalTrials.gov.
- GATEWAY (NCT07228117) — the one actually running. Recruiting since February 2026, 400 people across the US, Australia and New Zealand, randomised to no meal bolus, bolus at all meals, or bolus at will, for about 90 days. Its primary outcomes are descriptive — per-arm time in range (70–180 mg/dL / 3.9–10.0 mmol/L) and time below 70 mg/dL (3.9 mmol/L) — with primary completion in January 2027.2 It is registered against the NMX8 hardware that ships as MiniMed Flex, so it appears on this site under MiniMed Flex too. Its meal-bolus arms are the closest thing to a public test of the meal-optional idea.
- NEXUS (NCT07227805) — the experimental algorithm head-to-head against the 780G over 12 weeks, 116 people aged 2 and up with type 1 or type 2 diabetes. As of July 2026 it was not yet recruiting, with a planned start of June 2026.3
- ELEVATE (NCT07401901) — 230 adults with type 1 diabetes who are already on a commercial AID system with an HbA1c of 7.5% or above, across roughly 22 sites in Europe and the Middle East. Also not yet recruiting as of July 2026, planned start October 2026, primary completion December 2027.4
Read the endpoints carefully, because they set the honest expectation. Both NEXUS and ELEVATE are powered for non-inferiority in time in range — the question they ask is "is Vivera no worse than the loop you already use?", not "is it better?". That is a defensible design: the thing being won here is the removal of carb counting, and matching your current control while doing far less work would be a genuine win. But it means nobody should expect a headline jump in time in range from this programme.
Why the ambition matters anyway
The reason meal announcement has survived is not laziness of design — it is the speed of injected insulin. Insulin under the skin peaks 1.5–2 hours after it is dosed, while a meal hits the bloodstream in 30–60 minutes. An algorithm that only reacts once it sees glucose rising is starting the race late. That is why the fully-closed-loop research literature reports meal-detection latencies of 25–40 minutes and post-meal excursions that automation alone cannot fully catch.
Vivera does not repeal that physics. What it does is make the compromise a choice rather than a requirement — bolus when you can be bothered, don't when you can't, and let the algorithm cover the gap. For a lot of people that trade will be worth several points of time in range. It is also the first time a major manufacturer has committed to putting that choice in the hands of people who already own the pump.
What to watch
A software update delivering Vivera to existing 780G and MiniMed Flex users is reported for 2027 — but the source is a community recap of ADA 2026, not MiniMed.5 MiniMed has published no regulatory submission date and no launch timeline of its own. Until GATEWAY's meal-arm data appears, or NEXUS and ELEVATE actually start, everything here is a promise with a very small study behind it.
References
-
MiniMed unveils Vivera: a next-generation fully-closed-loop algorithm — coverage of the ATTD 2026 unveiling, 12 March 2026. Feasibility study: 14 adults and 13 children, three months. No time-in-range figures reported. ↩ ↩2
-
GATEWAY — Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living With Diabetes. NCT07228117, recruiting since 2 February 2026, n=400, primary completion January 2027. https://clinicaltrials.gov/study/NCT07228117 ↩
-
NEXUS — Evaluation of the Safety and Performance of the Novel Medtronic Experimental AID System (NMX8) in People Living With Diabetes. NCT07227805, not yet recruiting as of July 2026, planned start 15 June 2026, n=116, versus the MiniMed 780G. https://clinicaltrials.gov/study/NCT07227805 ↩
-
ELEVATE — Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental AID System (NMX8) in Adults Living With Type 1 Diabetes. NCT07401901, not yet recruiting as of July 2026, planned start 15 October 2026, n=230, ~22 EMEA sites, primary completion 4 December 2027. https://clinicaltrials.gov/study/NCT07401901 ↩
-
Closed-loop updates from ADA 2026 — community conference recap (not a MiniMed announcement); sole source for the reported 2027 software update to the 780G and MiniMed Flex. ↩
Coming soon
ETA · Investigational. No pivotal trial of the algorithm had started as of July 2026: NEXUS (NCT07227805, n=116, versus the 780G) was planned to start June 2026 and ELEVATE (NCT07401901, n=230, Europe/Middle East) is planned for October 2026 with primary completion in December 2027. A software update bringing Vivera to the MiniMed 780G and Flex is reported for 2027 in an ADA 2026 conference recap; MiniMed itself has announced no timeline and no regulatory submission date.
- →NEXUS (NCT07227805) — MiniMed's experimental algorithm versus the 780G over 12 weeks, n=116, non-inferiority in time in range · not yet recruiting; planned start June 2026
- →ELEVATE (NCT07401901) — n=230 adults with type 1 diabetes already on a commercial AID system with HbA1c ≥7.5%, ~22 sites across Europe and the Middle East, non-inferiority in time in range versus their existing system · not yet recruiting; planned start October 2026, primary completion December 2027
- →GATEWAY (NCT07228117) — the study actually running: 400 people randomised to no meal bolus, bolus at all meals, or bolus at will, with descriptive per-arm outcomes · recruiting since February 2026; primary completion January 2027
- →Software update delivering Vivera to existing MiniMed 780G and MiniMed Flex users (reported at ADA 2026, not confirmed by MiniMed) · reported for 2027
Sources
- [1]MiniMed unveils Vivera: a next-generation fully-closed-loop algorithm · news · 2026-03-12 — Unveiling coverage from ATTD 2026. Feasibility study = 14 adults and 13 children over three months. No time-in-range figures are given anywhere in the piece; the only efficacy datum is a single anecdote (a 13-year-old going from 8% to 6.7% HbA1c).
- [2]ELEVATE — Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental AID System (NMX8) in Adults Living With Type 1 Diabetes · registry — NCT07401901. Not yet recruiting as of July 2026; planned start 15 October 2026, primary completion 4 December 2027. n=230, ~22 EMEA sites, adults with type 1 diabetes already on a commercial AID with HbA1c ≥7.5%. Primary endpoint is non-inferiority in time in range (70–180 mg/dL / 3.9–10.0 mmol/L) versus their existing system. The registry record does not use the name "Vivera".
- [3]NEXUS — Evaluation of the Safety and Performance of the Novel Medtronic Experimental AID System (NMX8) in People Living With Diabetes · registry — NCT07227805. Not yet recruiting as of July 2026; planned start 15 June 2026. n=116, 12 weeks, versus the MiniMed 780G, enrolling people aged 2+ with type 1 or type 2 diabetes. Primary endpoint is non-inferiority in time in range. The registry record does not use the name "Vivera".
- [4]GATEWAY — Safety Evaluation of the MiniMed NMX8-AID System in Children and Adults Living With Diabetes · registry · 2026-06-08 — NCT07228117. Recruiting since 2 February 2026, n=400, US/Australia/New Zealand, primary completion January 2027. Randomises participants to no meal bolus, bolus at all meals, or bolus at will; primary outcomes are descriptive per-arm time in range and time below 70 mg/dL (3.9 mmol/L). The registry names the system NMX8-AID, not Vivera.
- [5]Closed-loop updates from ADA 2026 · community · 2026-06-25 — Community conference recap, not a MiniMed announcement. Sole source for the reported 2027 software update to the 780G and MiniMed Flex, so that timing is attributed rather than stated as fact.